靶向成纤维细胞激活蛋白与整合素αvβ3的肽类异二聚体放射性示踪剂
本研究设计并合成了双靶点肽类异二聚体FAP-RGD,通过细胞摄取、竞争结合、micro-PET/CT及生物分布评估其靶向成纤维细胞激活蛋白(FAP)与整合素αvβ3的性能。68Ga-FAP-RGD在临床前模型中较单体示踪剂显示更高的肿瘤摄取和更长的滞留时间,在健康志愿者和癌症患者中显示低背景活度和稳定积累,有效剂量为1.06×10⁻² mSv/MBq。
要点
- 68Ga-FAP-RGD对FAP和整合素αvβ3均具有高结合亲和力。
- 临床前模型中68Ga-FAP-RGD较68Ga-FAP-2286和68Ga-RGDfK肿瘤摄取更高、滞留更长。
- 177Lu-FAP-RGD在18.5和29.6 MBq活度下可有效抑制U87MG肿瘤生长。
核心结论
- 双特异性示踪剂68Ga-FAP-RGD利用多价效应,较相应单体显示更优的肿瘤摄取和滞留。
- 68Ga或177Lu标记的FAP-RGD临床前研究显示良好图像对比度和有效抗肿瘤反应。
- 尽管68Ga-FAP-RGD在临床诊断中表现优异,目前正在开展实验以优化FAP-RGD结构,提高其用于临床内放射治疗的潜力。
研究设计与样本
- FAP-RGD由FAP-2286与c(RGDfK)经多步有机合成制备。
- 通过细胞摄取和竞争结合实验研究68Ga-FAP-RGD的双受体结合特性。
- 在HT1080-FAP和U87MG肿瘤模型中使用micro-PET/CT和生物分布研究测定临床前药代动力学。
- 在U87MG肿瘤模型中评估177Lu-FAP-RGD的抗肿瘤疗效。
- 在健康志愿者和癌症患者中评估68Ga-FAP-RGD的辐射暴露和临床诊断性能。
主要发现
- 68Ga-FAP-RGD对FAP和整合素αvβ3均表现出高结合亲和力。
- 与68Ga-FAP-2286和68Ga-RGDfK相比,68Ga-FAP-RGD在临床前模型中显示增强的肿瘤摄取和更长的肿瘤滞留时间。
- 177Lu-FAP-RGD在18.5和29.6 MBq活度下可有效抑制U87MG肿瘤的体内生长。
- 68Ga-FAP-RGD的有效剂量为1.06×10⁻² mSv/MBq。
- 68Ga-FAP-RGD在大多数肿瘤病灶中显示低背景活度和长达3小时的稳定积累。
临床怎么用
- 原文未据此给出推荐。
局限性
- 尽管68Ga-FAP-RGD在临床诊断中表现优异,目前正在开展实验以优化FAP-RGD结构,提高其用于临床内放射治疗的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several studies have demonstrated the advantages of heterodimers over their corresponding monomers due to the multivalency effect. This effect leads to an increased number of effective targeted receptors and, consequently, improved tumor uptake. Fibroblast activation protein (FAP) and integrin αvβ3 are found to be overexpressed in different components of the tumor microenvironment. In our pursuit of enhancing tumor uptake and retention, we designed and developed a novel peptidic heterodimer that synergistically targets both FAP and integrin αvβ3. METHODS: FAP-RGD was synthesized from FAP-2286 and c(RGDfK) through a multi-step organic synthesis. The dual receptor binding property of 68Ga-FAP-RGD was investigated by cell uptake and competitive binding assays. Preclinical pharmacokinetics were determined in HT1080-FAP and U87MG tumor models using micro-positron emission tomography/computed tomography (micro-PET/CT) and biodistribution studies. The antitumor efficacy of 177Lu-FAP-RGD was assessed in U87MG tumor models. The radiation exposure and clinical diagnostic performance of 68 Ga-FAP-RGD were evaluated in healthy volunteers and cancer patients. RESULTS: Bi-specific radiotracer 68Ga-FAP-RGD exhibited high binding affinity for both FAP and integrin αvβ3. In comparison to 68Ga-FAP-2286 and 68Ga-RGDfK, 68Ga-FAP-RGD displayed enhanced tumor uptake and longer tumor retention time in preclinical models. 177Lu-FAP-RGD could efficiently suppress the growth of U87MG tumor in vivo when applied at an activity of 18.5 and 29.6 MBq. The effective dose of 68Ga-FAP-RGD was 1.06 × 10-2 mSv/MBq. 68Ga-FAP-RGD demonstrated low background activity and stable accumulation in most neoplastic lesions up to 3 h. CONCLUSION: Taking the advantages of multivalency effect, the bi-specific radiotracer 68Ga-FAP-RGD showed superior tumor uptake and retention compared to its corresponding monomers. Preclinical studies with 68Ga- or 177Lu-labeled FAP-RGD showed favorable image contrast and effective antitumor responses. Despite the excellent performance of 68Ga-FAP-RGD in clinical diagnosis, experimental efforts are currently underway to optimize the structure of FAP-RGD to increase its potential for clinical application in endoradiotherapy.
引用
- Liu K, Jiang T, Rao W, et al. Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin αvβ3. Eur J Nucl Med Mol Imaging. 2024. PMID: 38276986. doi:10.1007/s00259-024-06623-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。